Stammdaten
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
Unternehmen & Branche
| Name | Emmaus Life Sciences, Inc. |
|---|---|
| Ticker | EMMA |
| CIK | 0000822370 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 638.713 USD |
| Beta | 10,00 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 12,453,000 | -7,492,000 | -0.12 | 21,436,000 | -63,608,000 |
| 2025-09-30 | 10-Q | 3,378,000 | -2,076,000 | -0.03 | 20,756,000 | -59,488,000 |
| 2025-06-30 | 10-Q | 2,817,000 | -1,135,000 | -0.02 | 23,344,000 | -55,701,000 |
| 2025-03-31 | 10-Q | 2,406,000 | -2,330,000 | -0.04 | 22,478,000 | -58,601,000 |
| 2024-12-31 | 10-K | 16,653,000 | -6,453,000 | -0.10 | 23,602,000 | -56,479,000 |
| 2024-09-30 | 10-Q | 5,478,000 | 1,827,000 | 0.03 | 27,343,000 | -53,781,000 |
| 2024-06-30 | 10-Q | 5,377,000 | -2,184,000 | -0.03 | 25,939,000 | -57,014,000 |
| 2024-03-31 | 10-Q | 2,506,000 | -4,348,000 | -0.07 | 29,543,000 | -53,644,000 |
| 2023-12-31 | 10-K | 29,597,000 | -3,733,000 | -0.07 | 35,179,000 | -47,756,000 |
| 2023-09-30 | 10-Q | 5,018,000 | 67,000 | -0.01 | 47,453,000 | -36,330,000 |
| 2023-06-30 | 10-Q | 10,759,000 | -1,558,000 | -0.03 | 50,288,000 | -35,032,000 |
| 2023-03-31 | 10-Q | 6,753,000 | -3,451,000 | -0.07 | 48,946,000 | -37,363,000 |
| 2022-12-31 | 10-K | 18,390,000 | -10,625,000 | -0.21 | 48,225,000 | -34,091,000 |
| 2022-09-30 | 10-Q | 4,939,000 | -391,000 | -0.01 | 42,201,000 | -37,589,000 |
| 2022-06-30 | 10-Q | 4,287,000 | -8,892,000 | -0.18 | 45,989,000 | -34,635,000 |
| 2022-03-31 | 10-Q | 3,234,000 | -1,542,000 | -0.03 | 51,493,000 | -22,299,000 |
| 2021-12-31 | 10-K | 20,610,000 | -15,946,000 | -0.32 | 56,734,000 | -21,450,000 |
| 2021-09-30 | 10-Q | 5,766,000 | -3,151,000 | -0.06 | 60,057,000 | -15,101,000 |
| 2021-06-30 | 10-Q | 6,489,000 | 2,489,000 | 0.05 | 63,279,000 | -9,375,000 |
| 2021-03-31 | 10-Q | 5,335,000 | -8,422,000 | 62,223,000 | -12,676,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.